Announcements and Notices
VOLUNTARY ANNOUNCEMENT - Telitacicept Meets Primary Endpoint in Stage A of Phase III Clinical Trial for the Treatment of IgA Nephropathy in China
27
2025.08
58 Beijing Middle Road, Yantai Shandong, China.
-
- Company Wechat